ALNYLAM PHARMACEUTICALS, INC. Share-Based Compensation 2008-2025 | ALNY
What is share-based compensation?
Share-based compensation is the non-cash expense of stock options, restricted stock units, and other equity awards granted to employees.
What is ALNYLAM PHARMACEUTICALS, INC.'s current share-based compensation?
ALNYLAM PHARMACEUTICALS, INC. (ALNY) annual share-based compensation for 2025 was $348.2M, a 27.99% increase from 2024. ALNYLAM PHARMACEUTICALS, INC. share-based compensation for the quarter ending December 31, 2025 was $71.6M.
What was ALNYLAM PHARMACEUTICALS, INC.'s share-based compensation in 2024?
ALNYLAM PHARMACEUTICALS, INC. annual share-based compensation for 2024 was $272.1M, a 22.74% increase from 2023.
What was ALNYLAM PHARMACEUTICALS, INC.'s share-based compensation in 2023?
ALNYLAM PHARMACEUTICALS, INC. annual share-based compensation for 2023 was $221.7M, a 3.89% decline from 2022.
What is ALNYLAM PHARMACEUTICALS, INC.'s 5-year share-based compensation CAGR?
ALNYLAM PHARMACEUTICALS, INC. share-based compensation grew at a compound annual growth rate (CAGR) of 20.01% from FY2020 to FY2025, going from $139.9M to $348.2M over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $348.2M | +28.0% | 10-K |
| FY2024 | $272.1M | +22.7% | 10-K |
| FY2023 | $221.7M | -3.9% | 10-K |
| FY2022 | $230.6M | +39.2% | 10-K |
| FY2021 | $165.7M | +18.5% | 10-K |
| FY2020 | $139.9M | -20.0% | 10-K |
| FY2019 | $174.8M | +10.8% | 10-K |
| FY2018 | $157.8M | +70.0% | 10-K |
| FY2017 | $92.8M | +22.9% | 10-K |
| FY2016 | $75.5M | +65.0% | 10-K |
| FY2015 | $45.8M | +38.5% | 10-K |
| FY2014 | $33.1M | +59.7% | 10-K |
| FY2013 | $20.7M | +67.5% | 10-K |
| FY2012 | $12.4M | -25.9% | 10-K |
| FY2011 | $16.7M | -12.8% | 10-K |
| FY2010 | $19.1M | -3.1% | 10-K |
| FY2009 | $19.7M | +9.4% | 10-K |
| FY2008 | $18.0M | - | 10-K |